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Abstract
Background: Antineutrophil cytoplasmic antibody (ANCA) test is frequently used in the diagnostic evaluation of systemic
vasculitides, especially Wegener’s granulomatosis (WG). The test becomes positive in some other diseases like systemic lupus
erythematosus, rheumatoid arthritis, inflammatory bowel disease, infectious diseases and drug-induced conditions. Indirect
immunofluorescence (IIF) and enzyme linked immunosorbent assay (ELISA) are different techniques to detect ANCA. This study
was planned to evaluate the frequency of positive ANCA in connective tissue diseases and the control group.
Patients and methods: The study group was made up of patients with rheumatoid arthritis, systemic lupus erythematosus,
dermatomyositis, polymyositis, systemic sclerosis, and those with various vasculitic syndromes. We used the serum of couples
that were undergoing pre-marital screening tests as our control group. Both IIF and ELISA techniques were performed on the
two groups.
Results: Positive test result was detected in none of the 171 individuals in the control group. However, among 152 patients of the
study group, 24 were positive for p-ANCA, one was positive for c-ANCA, 5 were positive for anti-PR3, and 7 were positive for anti-
MPO. There was only one c-ANCA positive test result among the anti-PR3 positive cases. This case had a high titer of anti-PR3. We
did not find any association between anti-MPO by ELISA and p-ANCA pattern in IIF, instead the association between antinuclear
antibodies and p-ANCA positivity was statistically significant. c-ANCA and anti-PR3 tests were most frequently positive in WG
patients. Anti-MPO was more frequently positive in patients with systemic lupus erythematosus, dermatomyositis, and polymyositis.
Conclusion: Our data showed that neither p-ANCA nor anti-MPO is specific for the diagnosis of vasculitis and it seems that c-ANCA,
though specific for vasculitis, it is not sensitive for the detection of low-to-moderate antibody titres. This alongwith the problem
regarding the correlation of p-ANCA and anti-MPO underlines the necessity of using both methods (IIF and ELISA) in the search for
antineurophil cytoplasmic antibodies.
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Background
Antineutrophil cytoplasmic antibodies (ANCA) are now
used as markers for diagnosis and determining flare-up
of many systemic vasculitides. ANCA were first reported
in 1982 by Davis and his colleagues in a patient with
segmental necrotising glumerulonephritis1. Later on
ANCA were described in patients with systemic
vasculitides. Van der Woud and collaborators were the first
to suggest that ANCA yielding a diffuse granular
cytoplasmic fluorescence pattern on ethanol-fixed
neutrophils were a specific marker for Wegener’s
granulomatosis (WG) and a useful tool to assess disease
activity. Subsequently, target antigens for ANCA such as
myeloperoxidase (MPO) and proteinase-3 (PR3) have been
recognised1. When used to stain ethanol-fixed,
cytocentrifuged, normal human neutrophils by indirect
immunofluorescence, anti-PR3 produce a cytoplasmic
pattern of staining (c-ANCA) and anti-MPO produce a
perinuclear pattern (p-ANCA).
The number of diseases in which ANCA may be
encountered has been increasing. In 1997 Merkel et al
suggested that p-ANCA may be positive in many
connective tissue diseases including rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), Sjogren’s
syndrome, antiphospholipid syndrome, polymyositis (PM)
and dermatomyositis (DM)2.
Since the clinical features of vasculitides may be similar
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to connective tissue diseases, sometimes distinction
between them is difficult. Therefore, testing for ANCA – if
highly specific – could be of great importance in the initial
diagnostic evaluation of patients with a differential
diagnosis that includes both connective tissue disease and
vasculitis. Determination of the specificity of test for ANCA
in the diagnosis of vasculitis is crucial because the decision
of whether to pursue biopsies or initiate potentially toxic
immunosuppressive therapy may be made on the basis
of results of such testing.
We report the results of a descriptive analytical cross-
sectional study to determine the frequency of positive
ANCA test in a group of patients with various connective
tissue diseases. A standard testing system including
indirect immunofluorescence (IIF) and enzyme-linked
immunosorbent assay (ELISA) for anti-PR3 and anti-MPO
was used.
Patients and methods
In this descriptive, analytical cross-sectional study, 152
persons with various connective tissue diseases
participated as the patient group, and 171 healthy persons
as the control group.
All consecutive out-patients diagnosed as having RA, SLE,
PM or DM, systemic sclerosis (SSc), and systemic vasculitis
who attended the out-patient clinic of rheumatology (at
Hazrat-Rasool hospital) from December, 2001 to May, 2002
were included as “the study group”.  The diagnoses of
connective tissue diseases were determined using
American College of Rheumatology (ACR) criteria and
vasculitis was proven with a biopsy specimen in all patients
with systemic vasculitides. None of the patients had
received drugs such as allopurinol, penicillamine and
sulphasalazine for possible interference in the results of the
ANCA test3. We used 171 healthy persons undergoing
premarital screening tests as “the control group”.
Serum samples were collected from both the groups and
stored at minus 20 degrees centigrade. Both IIF and ELISA
techniques were performed on all samples. The laboratory
investigators who did the ANCA assays were blinded to
the diagnosis for each patient’s sample. We used Rayan-
teb kits for IIF tests and Organtec kits for ELISA. The positive
cut-off for anti-PR-3 ELISA was 5 U/ml and for anti-MPO
ELISA was 2.8 U/ml. Anti-nuclear antibodies (ANA) were
detected in this study by IIF using cultured HEp-2 cells. p-
ANCA must be distinguished from ANA. It has been shown
that the presence of antinuclear antibodies in the sera can
produce a p-ANCA pattern when ethanol-fixed
neutrophils are used as a substrate. Indeed, p-ANCA
pattern will be positive in the absence of antineutrophil
cytoplasmic antibodies if antinuclear antibodies are
present in the sera and differentiation between them is
difficult by usual immunofluorescence on ethanol-fixed
neutrophils.
IIF was done on each sample. The results of staining were
classified as having one of four patterns: c-ANCA, p-ANCA,
a-ANCA, or negative. Each sample was stained twice and
interpreted independently. Results of the first round of
staining were interpreted by one observer, and results of
the second round were interpreted by this observer and
a second observer. Both observers had considerable
experience in interpreting the results of
immunofluorescence staining of ANCA. If all three
readings were the same, the interpretation was considered
final. If the interpretation differed, a third slide was
prepared and re-examined by two observers. If at least
three of the five interpretations matched, the results were
considered final.
The ethical committee of Iran University of Medical
Sciences and Health Services approved the study.
Informed consent was obtained from all the participants.
The statistical procedures were: chi square and Fisher’s
exact tests. P-value was considered significant at less than
0.05.
Results
To detect the frequency of ANCA positivity in various
connective tissue diseases, we collected blood samples
of 323 persons, 152 patients and 171 healthy persons. Of
them 42 males were in patient group and 52 in control
group; 110 and 119 females were in patient and control
groups respectively. Mean age for the study group was
32.18 and for control group was 30.35 years. Mean disease
duration for study group was 5.49 years.
In the patient group there were 82 cases with RA (53.9%),
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32 cases with SLE (21.1%), 20 cases with DM or PM (13.2%),
9 cases with SSc (5.9%), 5 cases with WG (3.2%), and 4 cases
with other vasculitides (2.7%).
The final results of IIF and ELISA tests are shown in Table I.
None of the control patients had ANCA positivity by both
techniques. In the patient group, the frequency of p-ANCA
positivity by IIF was 24 (15.8%), 33.3% in SSc, 25% in SLE,
13.4% in RA. The frequency was low in PM and DM (5%).
c-ANCA was positive in only one patient (0.6%). Of 24 cases
that had positive p-ANCA, 8 (33%) were positive for
antinuclear antibodies. The association between
antinuclear antibodies and p-ANCA positivity was
statistically significant (p value < 0.001).
5 patients (4 with WG, 1 with RA) were found to have
anti-PR3 (3.2%) and 7 patients (3 with SLE, 3 with DM, 1
with RA) were found to have anti-MPO by ELISA (6.4%).
There were statistically significant relationship between
anti-MPO with DM, PM and SLE, and between anti-PR3
with WG (p value< 0.05).Titres of antibodies are shown
in Table II. There was no statistically significant
association between the positive results by IIF and
ELISA. Among five cases with anti-PR3 only one had c-
ANCA by IIF. Titre of anti-PR3 was higher in this case in
comparison with others (Table II). Among patients with
anti-MPO only one had p-ANCA by IIF and among 24
patients with p-ANCA only one had anti-MPO. No study
patients with connective tissue diseases who had
positive results by ELISA or IIF were found to have
evidence of vasculitis. We did not find any atypical
ANCA (a-ANCA).
Table I: Results of tests for ANCA in connective tissue diseases.
Test→ No. Positive % Positive % Positive % Positive %
↓Disease c-ANCA p-ANCA anti-PR3 anti-MPO
SLE 32 0 0 8 25 0 0 3 9.4
RA 82 0 0 11 13.4 1 1.2 1 1.2
SSc 9 0 0 3 33.3 0 0 0 0
PM DM 20 0 0 1 5 0 0 3 15
WG 5 1 20 0 0 4 80 0 0
Other 4 0 0 1 25 0 0 0 0
Vasculitides
Total 152 1 0.6 24 15.8 5 3.2 7 4.6
Table II: Titres of anti-MPO and anti-PR3 antibodies.
Sex Disease Anti-MPO Anti-PR3
(U/ml) (U/ml)
M DM 12.98 –
M DM 32.45 –
M DM 9.38 –
F WG – 12.86
F WG – 10.4
F WG – 12.67
M WG – 120.4
F SLE 15.33 –
F SLE 8.49 –
F SLE 98.16 –
F RA – 6.26
F RA 10.77 –
Discussion
The aim of the present study was to measure the
frequency of ANCA test positivity in patients with various
connective tissue diseases. We found a high frequency
of antibodies to neutrophils detected by IIF, but a low
frequency of anti-PR3 or anti-MPO detected by ELISA. c-
ANCA was not found in connective tissue diseases but
p-ANCA was found in many serum samples. This was
shown by Merkel et al in 1997 too. Among five cases with
anti-PR3, only one had c-ANCA by IIF. Titre of anti-PR3
was higher in this case in comparison with others (Table
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II). So it may be infered that IIF may not be a sensitive
technique for detection of low antibody titres, although
it is a reliable marker of vasculitis because it was positive
only in a case of WG, and we did not find it positive in
other diseases.
Although, Hagen and co-workers have shown a positive
relationship between p-ANCA and the presence of anti-
MPO4, there was no relationship between them in this
study. Maybe it is the result of the presence of
cytoplasmic antibodies other than MPO, or antinuclear
antibodies, because we know that antinuclear antibodies
(ANA) can produce staining that cannot be distinguished
from p-ANCA which is produced by anti-MPO2-5. We
found a strong association between serum samples that
were positive for ANA and those that were positive for
p-ANCA. 33% of p-ANCA positive sera were ANA positive
too in this study. This finding is compatible with Merkel’s
study.
In this study, we found anti-MPO in connective tissue
diseases, especially DM and SLE.
Because of the presence of these problems with the
application of ANCA assays, many investigators suggest
using ELISA at the initial stage of ANCA detection and IIF
for confirmation of positive findings6.
In conclusion, our data show that neither p-ANCA nor
anti-MPO is specific for vasculitis, and it seems that c-
ANCA though specific, is not sensitive for the detection
of low-to-moderate antibody titres in vasculitis. This
alongwith the problem regarding the correlation of p-
ANCA and anti-MPO, and the possibility of the
interference of ANA on the result of ANCA test by IIF,
underlines the necessity of using both methods (IIF and
ELISA) in the search for antineutrophil cytoplasmic
antibodies.
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